Journal of Clinical & Experimental Pharmacology

Q Ping Dou

Q Ping Dou
Professor, Oncology, Pharmacology and Pathology
Wayne State University, USA

Biography

Dr. Q. Ping Dou is Professor of Oncology, Pharmacology and Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI. Dr. Dou obtained his B.S. degree in chemistry from Shandong University in 1981, Ph.D. degree in chemistry from Rutgers University in 1988, and postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School from 1988 to 1993 (Mentor: Arthur B. Pardee). Dr. Dou has extensive experience in the fields of drug discovery, chemoprevention, natural products, proteasome inhibitors, cell cycle and apoptosis. He has published ~214 peer-reviewed research and review articles, many of those in journals of the highest quality, and also holds more than 10 patents. He has extensive experience in professional service, including various study sections, several advisory and editorial boards, and committees. He has mentored numerous graduate students, post-doctoral fellows and junior faculty.

Research Interest

Dr. Dou’s commitment to cancer research is centered on targeted therapies, drug discovery, natural products, and chemoprevention. The main objective in his laboratory is aimed at discovering molecular targets of natural and synthetic small molecules in pre-clinical studies, followed by validation in targeted clinical trials. His laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells, and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. His laboratory has also shown that some tea polyphenols, curcumin, DIM, medicinal compounds and metal complexes potently and specifically inhibit the chymotrypsin-like activity of the proteasome in vitro and in vivo. Most recently, he has found that (i) novel epigallocatechin gallate (EGCG) analogs and BR-DIM activate AMP-activated protein kinase (AMPK) pathway, target cancer stem cells and induce apoptosis; (ii) novel EGCG and curcumin analogs increase efficacy of bortezomib (BTZ) in human multiple myeloma (MM) cells.